March 19 (Reuters) - Collegium Pharmaceutical ( COLL )

on Thursday said it will buy an attention deficit hyperactivity

disorder drug from privately held Corium Therapeutics for up to

$785 million, expanding its portfolio of ADHD treatments.

* Collegium said it will buy the drug, called Azstarys,

for $650 million in cash and may pay Corium up to $135 million

more, contingent on certain milestones.

* Collegium's portfolio already includes another ADHD

drug called Jornay PM.

* Azstarys treats ADHD in people six years and older,

with the capsule combining a fast-acting and a long-acting

stimulant in one dose, the company said.

* Collegium expects Azstarys to bring in over $50

million in net revenue in the second half of 2026.

* Most U.S. patents supporting the product run through

December 2037, according to the company.

* Collegium will fund the purchase with cash on hand and

$300 million it plans to borrow under an existing loan facility.

* The deal is expected to close in the second quarter of

2026 and will be immediately accretive to adjusted core profit,

the company said.